Keyword Analysis & Research: tolvaptan rems

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
tolvaptan rems	1.81	0.4	6222	1	14
tolvaptan	1.27	0.9	8523	7	9
rems	0.09	0.2	2204	92	4

Keyword	CPC	PCC	Volume	Score
tolvaptan rems	0.39	0.8	7248	29
tolvaptan rems program	0.43	0.1	4134	19
tolvaptan rems enrollment	1.22	0.8	2660	6
fda rems tolvaptan	1.57	0.4	1857	43

REMS Program | HCP JYNARQUE® (tolvaptan) tablets
jynarquehcp.com:443

https://www.jynarquehcp.com:443/rems-program

WebFind information on the REMS Program and how to become certified to prescribe JYNARQUE® (tolvaptan). See FULL PRESCRIBING INFORMATION, including BOXED WARNING.

DA: 31 PA: 12 MOZ Rank: 39

Risk Evaluation and Mitigation Strategy (REMS) Document …
fda.gov:443

https://www.accessdata.fda.gov:443/drugsatfda_docs/label/2018/204441s002lbl.pdf

WebWHAT IS THE JYNARQUE REMS? This Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage the risk of serious and potentially fatal liver injury associated with use of...

DA: 99 PA: 74 MOZ Rank: 20

FULL PRESCRIBING INFORMATION - Food and Drug …
fda.gov:443

https://www.accessdata.fda.gov:443/drugsatfda_docs/label/2018/204441lbl.pdf

Webprogram called the JYNARQUE REMS Program (5.2)-----INDICATIONS AND USAGE-----JYNARQUE is a selective vasopressin V 2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal ... JYNARQUE (tolvaptan) is supplied as non-scored, blue, shallow-convex, immediate release tablets, debossed

DA: 51 PA: 56 MOZ Rank: 87

REMS Program & Liver Function | JYNARQUE® (tolvaptan) tablets
jynarque.com:443

https://www.jynarque.com:443/risks-and-rems

WebLearn about the JYNARQUE® (tolvaptan) risk evaluation and mitigation strategy (REMS) program & how monitoring lab work can reduce your risk of liver injury. See IMPORTANT SAFETY INFO and FULL PRESCRIBING INFO, including BOXED WARNING and MEDICATION GUIDE.

DA: 41 PA: 49 MOZ Rank: 68

JYNARQUE REMS Program
jynarquerems.com:443

https://www.jynarquerems.com:443/

WebThis Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage the risk of serious and potentially fatal liver injury associated with use of JYNARQUE and is required by the Food and Drug Administration (FDA) to ensure the …

DA: 77 PA: 59 MOZ Rank: 22

Treatment Resources | HCP JYNARQUE® (tolvaptan) tablets
jynarquehcp.com:443

https://www.jynarquehcp.com:443/treatment-resources

WebFind treatment resources for HCP’s and patients for JYNARQUE® (tolvaptan), including information on preparing for patient visits, prescribing JYNARQUE and specialty pharmacies. See FULL PRESCRIBING INFORMATION, including BOXED WARNING.

DA: 9 PA: 32 MOZ Rank: 4

Evaluating the impact of a Risk Evaluation and Mitigation …
oup.com:443

https://academic.oup.com:443/ckj/article/15/8/1553/6547019

WebMar 11, 2022 · In interim data on >6000 tolvaptan REMS patients, <1% experienced possible severe DILI. Monthly monitoring, as described in the tolvaptan prescribing information, enables the prompt detection of liver enzyme abnormalities and appropriate drug discontinuation.

DA: 100 PA: 43 MOZ Rank: 35

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
nih.gov:443

https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC6171265/

WebSep 18, 2018 · All physicians prescribing tolvaptan for ADPKD must be trained and certified in its safe use (see the REMS website for details: https://www.jynarquehcp.com/rems-program). Failure to comply with this testing prohibits the specialty pharmacy from dispensing the medication to the patient.

DA: 86 PA: 69 MOZ Rank: 3

Tolvaptan and Number Needed to Harm in Autosomal Dominant …
kidneymedicinejournal.org:443

https://www.kidneymedicinejournal.org:443/article/S2590-0595(24)00013-X/fulltext

WebFeb 20, 2024 · In the interim analysis of 6,711 patients treated with tolvaptan through the REMS program, <1% experienced possible severe drug-induced liver injury, confirming that frequent monitoring enables timely identification of liver enzyme abnormalities and appropriate drug discontinuation.

DA: 16 PA: 38 MOZ Rank: 37

Assessing Risk of Progression in ADPKD - PMC - National …
nih.gov:443

https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC8763158/

WebThe selective arginine vasopressin V2 receptor antagonist, tolvaptan, is an oral agent that reduces the rate of increase in total kidney volume (TKV) and slows the decline in GFR, likely resulting in delay of kidney failure.

DA: 34 PA: 65 MOZ Rank: 91